Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto.

Novartis AG (NVS) reports robust financial performance with significant product sales growth, while addressing potential ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of $1.

Novartis AG is paying nearly $1 billion up front to buy privately held Anthos Therapeutics Inc. in a deal that eventually could top out around $3.1 billion. Novartis, coming back to where it started ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...